NCT06035497 2025-05-14
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Phase 1/2 Recruiting
Bristol-Myers Squibb
Chongqing Precision Biotech Co., Ltd
Kyowa Kirin Co., Ltd.